XYL Reiterate Outperform and $168 PT - counter to the lingering concerns of some investors, remain confident in Xylem's normalized organic g
XYL Reiterate Outperform and $168 PT - counter to the lingering concerns of some investors, remain confident in Xylem's normalized organic growth and margin expansion trajectory @ OPCO
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.